SCHEMBL3269992

SCHEMBL3269992

Cc1noc(NC(=O)N2CCN(c3nccc(-c4ccccc4F)n3)CC2)c1C

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FAAH O00519 9/20 0.54
HCAR2 Q8TDS4 1/20 0.46
KMT2A Q03164 2/20 0.44
GAA P10253 1/20 0.42
ALDH1A1 P00352 2/20 0.42
PKM P14618 1/20 0.42
TRPV1 Q8NER1 1/20 0.41
DGAT1 O75907 1/20 0.41
CA9 Q16790 2/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
STS P08842 1/20 0.40
KDM4E B2RXH2 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3268031 0.93 FAAH (0.64) FAAHHCAR2KMT2AGAAALDH1A1
SCHEMBL3268215 0.90 FAAH (0.51) FAAHHCAR2KMT2AGAAALDH1A1
SCHEMBL3268706 0.89 FAAH (0.63) FAAHHCAR2ALDH1A1PKMKDM4E
SCHEMBL3268997 0.89 FAAH (0.64) FAAHHCAR2KMT2AALDH1A1PKM
SCHEMBL3268754 0.87 HCAR2 (0.62) FAAHHCAR2KMT2AGAADGAT1
SCHEMBL3272722 0.85 FAAH (0.51) FAAHHCAR2ALDH1A1PKMTRPV1
SCHEMBL3270175 0.85 FAAH (0.63) FAAHHCAR2KMT2AALDH1A1PKM
SCHEMBL3275494 0.84 FAAH (0.61) FAAHHCAR2KMT2AALDH1A1PKM
SCHEMBL3275040 0.84 FAAH (0.54) FAAHHCAR2KMT2AALDH1A1PKM
SCHEMBL3274898 0.82 FAAH (0.51) FAAHALDH1A1TRPV1DGAT1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234389-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-16 US disclosed
US-20100234389-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-16 US disclosed
US-20100234389-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-16 US disclosed
EP-2199282-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-06-23 EP disclosed
US-20090163508-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
US-20090163508-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed
US-20090163508-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234389-A1 AMIDE COMPOUND FAAH, FAAH2, NAAA FAAH 1/4885HCAR2 34/4885KMT2A 404/4885
US-20090163508-A1 AMIDE COMPOUND FAAH, FAAH2, NAAA FAAH 1/4885HCAR2 34/4885KMT2A 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.